Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article synthesizes current evidence regarding psychedelics' effects on nature relatedness and social connectedness, examining underlying mechanisms through the framework of self-other overlap. Psychedelics appear to facilitate self-expansion through two complementary mechanisms: ego dissolution, which temporarily alters self-boundaries, and enhanced emotional processing, which increases empathic concern. While studies demonstrate promising effects, interpretation is complicated by methodological challenges including functional unblinding, reliance on self-reports, and small sample sizes. We propose a multidimensional model of connectedness that distinguishes between perceptual, emotional, and epistemic domains, each showing distinct patterns in acute and enduring effects. Future research would benefit from behavioral measures, active placebos, and careful consideration of contextual factors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.copsyc.2025.101992DOI Listing

Publication Analysis

Top Keywords

psychedelics connectedness
4
connectedness natural
4
natural social
4
social worlds
4
worlds examination
4
examination evidence
4
evidence proposed
4
proposed conceptual
4
conceptual framework
4
framework suggests
4

Similar Publications

Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article synthesizes current evidence regarding psychedelics' effects on nature relatedness and social connectedness, examining underlying mechanisms through the framework of self-other overlap. Psychedelics appear to facilitate self-expansion through two complementary mechanisms: ego dissolution, which temporarily alters self-boundaries, and enhanced emotional processing, which increases empathic concern.

View Article and Find Full Text PDF

Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.

Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.

View Article and Find Full Text PDF

MDMA as well as amphetamine and alcohol increase feelings of social closeness in healthy adults.

Sci Rep

December 2024

Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.

Psychoactive drugs such as alcohol and stimulants are typically used in social settings such as bars, parties or small groups. Yet, relatively little is known about how social contexts affect responses to drugs, or how the drugs alter social interactions. It is possible that positive social contexts enhance the rewarding properties of drugs, perhaps increasing their potential for repeated use and abuse.

View Article and Find Full Text PDF

There is a disparity between contemporary scientific investigations into psychedelic phenomena and their 20-century counterparts, notably the lack of examination of psychedelic experiences within group settings. Whereas early research studies from the 1950s to the 1970s explored communal settings in psychedelic-assisted therapy (PAT), today's resurgence of scholarship in the field primarily considers individualised, often clinical, settings. Consequently, there is an absence of empirical research and theoretical innovation on collective psychedelic contexts, for example, how social connectedness occurs relationally and what its impacts are.

View Article and Find Full Text PDF

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.

Trials

May 2024

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Waikato Clinical Campus, Peter Rothwell Academic Centre, Pembroke Street, Hamilton, 3240, New Zealand.

Background: Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in this population. Several centres have reported that one dose of the serotonergic psychedelic psilocybin, combined with therapeutic support, improves these symptoms for up to 6 months in this patient group. Drawing upon related therapeutic mechanisms, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy may have the potential to achieve similar, positive mental health outcomes in this group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!